NasdaqHealth CareBiological Products, (No Diagnostic Substances)BOSTON, MA

Compass Therapeutics, Inc. CMPX

Ask your AI

Estimated market cap $139.35M180.09M shares, shares as of Nov 5, 2026CIK 1738021

Insider trades, 12 mo

3 buys · 0 sells

$78.5K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

216

92.0% of shares · 85 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Compass Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 9, 2026 · Quarter ended Sep 30, 2026

AI No AI summary for this 10-Q: the draft did not pass our accuracy checks.

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Compass Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

3 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Sep 24, 2026. Insiders have two business days to file.

Recent insider trades

Neil Lerner Chief Accounting Officer	Sep 24 Form 4 ↗	Buy	+$2,850 2,500 sh @ $1.14	-30.2%
Neil Lerner Chief Accounting Officer	Apr 29 Form 4/A ↗	Buy	+$28.4K 15,000 sh @ $1.89	-59.7%
Jonathan Anderman General Counsel	Apr 29 Form 4/A ↗	Buy	+$47.3K 25,000 sh @ $1.89	-59.7%
Thomas J. Schuetz CHIEF EXECUTIVE OFFICER, Director	May 27, 2025 Form 4 ↗	Buy	+$21.1K 10,000 sh @ $2.11	-90.9%
Carl L. Gordon Director, 10% owner	Apr 9, 2025 Form 4 ↗	Sale	−$5.7M 3.57M sh @ $1.59	-93.3%

All CMPX insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

165.71M shares

216 funds report CMPX. Values checked against market prices.

Funds own 92% of shares (Q2 2026)

216 funds hold the stock.

Q3 2026: 38% · 5,560 of ~8,900 funds reported so far

Q2 202578%
Q3 202586%
Q4 202592%
Q1 202696%
Q2 202692%
Q3 2026 (so far)38%

Reports for the quarter ending Sep 30, 2026 are still coming in (111 positions so far, against 230 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 65 new, 85 added to, 44 trimmed, 50 exited since Q1 2026.

Top 13F holders
#
1	Tang Capital Management LLC 13F ↗	17.99M	$39.4M	+7.1%
2	Orbimed Advisors LLC 13F ↗	15.22M	$33.3M	unchanged
3	Montanova Capital, LLC 13F ↗	14.10M	$30.9M	-1.4%
4	BlackRock, Inc. 13F ↗	11.28M	$24.7M	+18.7%
5	State Street Corp 13F ↗	9.95M	$21.8M	+48.7%
6	Enavate Sciences GP, LLC 13F ↗	7.79M	$17.1M	unchanged
7	Vivo Capital, LLC 13F ↗	7.76M	$17.0M	-18.7%
8	Vanguard Capital Management LLC 13F ↗	6.12M	$13.4M	+1.4%
9	Palo Alto Investors LP 13F ↗	5.83M	$12.8M	+285.1%
10	Millennium Management LLC 13F ↗	4.71M	$10.3M	+457.0%

Download CSV Every fund that holds CMPX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Compass Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Compass Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q4 2021	37	—	63.57M	$201.6M
Q1 2022	34	-3	62.38M	$85.4M
Q2 2022	33	-1	61.88M	$163.9M
Q3 2022	38	+5	67.38M	$153.7M
Q4 2022	55	+17	79.83M	$401.4M
Q1 2023	72	+17	87.16M	$285.0M
Q2 2023	73	+1	90.48M	$287.7M
Q3 2023	76	+3	89.72M	$176.7M
Q4 2023	77	+1	86.40M	$134.8M
Q1 2024	78	+1	94.92M	$187.9M
Q2 2024	82	+4	92.91M	$93.5M
Q3 2024	79	-3	92.23M	$169.7M
Q4 2024	92	+13	101.39M	$147.0M
Q1 2025	108	+16	108.50M	$206.1M
Q2 2025	103	-5	108.40M	$281.9M
Q3 2025	125	+22	153.07M	$535.7M
Q4 2025	172	+47	164.13M	$881.4M
Q1 2026	201	+29	173.24M	$919.1M
Q2 2026	216	+15	165.71M	$363.4M
Q3 2026	107	-109	69.02M	$71.8M

Each point is a quarter-end, from Q4 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (20454B104). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes6 in 12 mo 8-K events2 in 90 days Patents4 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive pay2 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials4 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Compass Therapeutics, Inc.
Address: 80 GUEST STREET, BOSTON, MA 02135
Phone: 617-500-8099
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: CMPX (Nasdaq)
Former names: Olivia Ventures, Inc. (until 2020)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.7738−$0.05 (−5.63%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.6846 · High $0.8967Nov 13, 2026

Aug 13, 2026Low $0.6846 · High $2.53Nov 13, 2026

Nov 13, 2025Low $0.6846 · High $6.69Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.